For the quarter ending 2025-06-30.
| Income Statement | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 0 | - | 19,450.333 | 5,426 |
| Cost of goods sold | 239,040 | - | 2,645,027.5 | 286,028 |
| Gross loss | -239,040 | - | -2,615,852 | -280,602 |
| Sales and marketing | 0 | - | 244,415.5 | 216,605 |
| Research and development | 349,951 | 307,730 | 427,929.5 | 14,776 |
| Loss on impairment of long-lived assets | - | - | 414,958.75 | - |
| General and administrative | 1,199,323 | 1,665,822 | 3,042,417.25 | 1,414,026 |
| Total operating expenses | 1,549,274 | 1,973,552 | 4,129,721 | 1,645,407 |
| Loss from operations | -1,788,314 | -1,973,552 | -6,745,573 | -1,926,009 |
| Legal settlement | - | - | 274,055.5 | - |
| Other income (expense), net | 25,000 | 41,368 | 314,097 | -468,978 |
| Unrealized gain (loss) on marketable securities | -7,457 | -71,707 | -79,746.5 | -240,743 |
| Realized gain on marketable securities | 94,492 | 211,062 | 342,673 | 562,627 |
| Interest income | 7,961 | 26,240 | 127,349 | 89,060 |
| Change in fair value - warrant liability | 13,254,700 | -1,080,600 | -1,446,400 | -126,600 |
| Change in fair value - derivative liability | 1,130,000 | 1,531,000 | 420,486.25 | 2,408,000 |
| Vendor settlement | - | - | 161,958.25 | - |
| Consent and waiver fee series h-7 | 350,000 | - | - | - |
| Total other income (expense), net | -12,354,704 | 2,818,563 | 2,135,245 | 2,476,566 |
| Net income (loss) prior to provision for income taxes | -14,143,018 | 845,011 | -4,610,328 | 550,557 |
| Provision for income taxes | 0 | - | 0 | - |
| Net income (loss) | -14,143,018 | 845,011 | -4,610,328 | 550,557 |
| Accretion of discounts to redemption value of series h-7 convertible preferred stock | 1,562,047 | 1,686,854 | -2,374,517.5 | -1,506,979 |
| Dividends earned on series h-7 convertible preferred stock | 870,461 | 833,733 | 568,889.5 | 741,172 |
| Net income (loss) attributable to common stockholders | -16,575,526 | -1,675,576 | -7,553,735 | -1,697,594 |
| Basic weighted average common stock outstanding | 554,989 | 8,541,466 | -3,154,260 | 6,863,234 |
| Diluted weighted average common stock outstanding | 554,989 | 8,541,466 | -8,665,775 | 6,863,234 |
| Net income (loss) per share basic | -29.87 | -0.2 | -1.275 | -0.25 |
| Net income (loss) per share diluted | -29.87 | -0.2 | -0.955 | -0.25 |
AYRO, Inc. (AYRO)
AYRO, Inc. (AYRO)